Denka Company Limited
FY2026 (Fiscal year ending March 2027) Q2 Financial Summary
Against a backdrop of increased demand related to AI and power infrastructure, the FY2026 Q2 results showed a substantial increase in operating profit and an upward revision to the full-year forecast on a cumulative basis. Key drivers were the reflection of the DPE suspension impact and inventory effects. Life Innovation was affected by reduced shipments of rapid antigen test kits, but the overall company revised guidance upward. Dividend is expected to be maintained at 100 yen per share.
Key Figures
- Revenue: 2,087 hundred million yen (FY2026 H1 results)
- Operating Income: 247 hundred million yen (FY2026 H1 results)
- Net Income Attributable to Owners of Parent: 69 hundred million yen (FY2026 H1 results)
AI要約
Summary of Results
Consolidated results for FY2026 Q2 were revenue of 2,087 hundred million yen (Year-over-Year +408 hundred million yen), operating income of 247 hundred million yen (Year-over-Year +150 hundred million yen), and net income attributable to owners of parent of 69 hundred million yen (Year-over-Year +30 hundred million yen), securing a substantial increase in profitability. Expansion of demand related to AI and power infrastructure and the effect of DPE operational suspension contributed. There was an adjustment in shipments of rapid antigen diagnostic kits, but on a company-wide basis guidance was revised upward.
Outlook and Dividend
Full-year earnings forecasts for FY2026 are expected to be revised upward, reflecting continued demand for AI-related and power infrastructure applications and the net contribution from inventory effects. As for dividend policy, while targeting a total shareholder return ratio of about 56%, the dividend per share will be maintained. A management briefing is scheduled for December.
Denka Company Limited
Company overview · Stock price · Financial data · All IR
